# Sarcomatoid differentiation (RCC)

Source: https://onco.cc/terms/sarcomatoid-rcc/  
OnCo record `sarcomatoid-rcc` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A spindle-cell change found in about 10% of kidney cancers that makes them aggressive and, unexpectedly, unusually responsive to immunotherapy.

## Summary

Sarcomatoid RCC (any histology) has median survival under a year on TKIs alone, but in CheckMate 214 nivolumab-ipilimumab produced ORR ~60% and complete responses in ~20%, with OS HR ~0.45. High PD-L1 and immune infiltration explain the paradox. Guidelines favour IO-based regimens in sarcomatoid disease.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sarcomatoid_carcinoma
- Wikipedia: https://en.wikipedia.org/wiki/Sarcomatoid_carcinoma

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- trials: [CheckMate 214](https://onco.cc/trials/checkmate-214/)
- pairings: [IMDC risk → first-line regimen choice (RCC)](https://onco.cc/pairings/risk-directed-first-line-rcc/)

---
JSON: https://onco.cc/api/v1/entities/sarcomatoid-rcc.json